Fore Biotherapeutics

Our team came together for an energizing offsite focused on strategy, scientific alignment, and collaboration as we work to advance our mission to develop innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers.

The Fore team recently joined forces with, @HeadfortheCure for a 5K run dedicated to raising awareness and support for patients and families impacted by brain cancer. #Biotech #Oncology

Attending #ASCO25? We’re presenting a poster highlighting the study design of the global registration-intended FORTE Master Protocol. Learn more: fore.bio/fore_biotherap…

FORE Bio will participate in the Jefferies Global Healthcare Conference on Tuesday, June 3. Management will host and participate in one-on-one meetings at the conference. Learn more: fore.bio/fore_biotherap…

Fore completed a $38M Series D-2 financing, adding to $75M raised in prior Series D & D-1 financings totaling $113M. Leading healthcare investors participated including SR One, Medicxi, OrbiMed, HBM, Wellington, Novartis Venture Fund, Cormorant, and 3B: tinyurl.com/3mra2wb8

Analysis presented at #AACR shows changes in ctDNA accurately detect BRAF mutations from tumor biopsies and changes in variant allele frequency of BRAF mutation in ctDNA may be a surrogate marker for monitoring disease. Learn more: fore.bio/fore_biotherap…

We’re presenting new plixorafenib results with @MSKCancerCenter at #AACR demonstrating pharmacodynamic effect in clinical tumor biopsies and decreased V600E mutant allele frequency in ctDNA of 85% of patients. Learn more: fore.bio/fore_biotherap…

Attending #AACR 2025? Check out our 2 posters featuring plixorafenib targeting BRAF-mutated tumors, including ctDNA results from a previously completed Phase 1/2a study and the study design from our Phase 2 FORTE basket study. Learn more: fore.bio/fore_biotherap…

Today, William Hinshaw, CEO of Fore Bio, will be presenting at the Raymond James Private Biotech Symposium at 4:00 p.m. ET. Please contact Argot Partners ([email protected]) to schedule one-on-one meetings with the management team. Learn more: bit.ly/4k7E6rK

Fore Bio will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14 at 5:30 p.m. PT. Please contact Argot Partners ([email protected]) to schedule one-on-one meetings with the management team. Learn more: businesswire.com/news/home/2024…

Wishing our team, partners and supporters a very Happy Holiday season and a joyful New Year. #TeamFore

FORE Bio will participate in the Wells Fargo Virtual Private Biotech Symposium on Dec. 12. William Hinshaw, Chief Executive Officer and Michael Byrnes, Chief Financial Officer will host and participate in one-on-one meetings at the conference. Learn more: businesswire.com/news/home/2024…

Today, November 20, and tomorrow, November 21, William Hinshaw, Chief Executive Officer and Michael Byrnes, Chief Financial Officer will host and participate in one-on-one meetings at the Jefferies London Healthcare Conference.

Today, William Hinshaw, Chief Executive Officer of FORE Bio will provide a corporate presentation at the Stifel 2024 Healthcare Conference. Management will host and participate in one-on-one meetings.

During November, Fore will participate in the Stifel 2024 Healthcare Conference and the Jefferies London Healthcare Conference. To request a meeting with management contact Argot Partners at [email protected]. Learn more here: businesswire.com/news/home/2024…

Last week, William Hinshaw, Chief Executive Officer of FORE Bio sat for a fireside chat at the RBC Capital Markets 2024 Virtual Biotechnology Private Company Conference. A link to the webcast is available on Fore’s website: fore.bio/news/

Last week, William Hinshaw, Chief Executive Officer of FORE Bio gave a corporate presentation at the UBS 2024 Virtual Biotechnology Private Company Symposium. A link to the webcast is available on Fore’s website: fore.bio/news/

Attending Cantor’s 2024 Global Healthcare Conference? Today, William Hinshaw, Chief Executive Officer and Michael Byrnes, Chief Financial Officer of FORE Bio will host and participate in one-on-one meetings. #CantorHCC

Today, FORE Bio announced that management will participate in several upcoming investor conferences. Learn more: businesswire.com/news/home/2024…

Today, we are thrilled to announce that we have brought on a new Chief Financial Officer, Michael Byrnes. Click here to read the full release businesswire.com/news/home/2024…